Q3 2021

Filed Nov 10, 2021 · 10-Q · 41 days after period end · 0001410578-21-000089

Q3 2021 · 10-Q

Revenue—

Net Income

-$12.43M

N/M vs Q3 2020

EPS Diluted

-$0.15

N/M vs Q3 2020

Operating Income-$10,023,538N/M

Operating Cash Flowderived-$7,535,862N/M

Same quarter

Metric	Q3 2021	Q3 2020	Q3 2019	Q3 2018
Revenue	—	$0.00	$0.00	$0.00
Net Income	-$12.43M	-$7.37M	-$5.46M	-$4.39M
EPS Diluted	-$0.15	-$0.16	-$0.12	-$0.32

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR